BIOABSORBABLE STENTS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Bioabsorbable Stents in Thousand Units. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 16 companies including many key and niche players such as -

Abbott Laboratories
Amaranth Medical, Inc.
Arterial Remodeling Technologies SA
BIOTRONIK SE & Co. KG
Elixir Medical Corporation
Kyoto Medical Planning Co.
Ltd.
REVA Medical, Inc.


Click here to request a full list of companies covered in the report...

Code : MCP-6396
Price : $4200
Companies : 16
Pages : 108
Date : March 2013
Market Data Tables : 11

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   A Prelude.....II-1
Evolution of Coronory Stents.....II-1
1$100
   Current Global Coronory Stent Scenario – A Few Key Facts.....II-2
Bioabsorbable Stents Poised to Replace Drug-Eluting Stents in Future.....II-2
1$100
   Market Overview.....II-3
Current & Future Analysis.....II-3
1$100
   Growth Drivers.....II-4
Restenosis - the Real Growth Driver.....II-4
Aging Population Propels Coronary Stents Market.....II-4
Limitations and Challenges Ahead.....II-4
1$100
   Technological Challenges.....II-5
Safety- Efficacy Factor.....II-5
Regulatory Challenges.....II-5
Price Factor.....II-5
Threats to Coronary Stents – Alternative Therapies/Devices.....II-5
1$100
   Cell Transplantation – A Threat to Coronary Stents.....II-6
Regulations for Conducting Clinical Trials Bioabsorbable Stents in Select
  Regions.....II-6
The United States.....II-6
Europe.....II-6
1$100
   Australia.....II-7
Competitive Scenario.....II-7
Focus on Select Bioabsorbable Stents.....II-7
Absorb® (Abbott Laboratories, US).....II-7
1$100
   ART Bioabsorbable Stent (Arterial Remodeling Technologies, France).....II-8
DREAMS (BIOTRONIK, Germany).....II-8
DESolve™ Coronary Scaffold (Elixir Medical, US).....II-8
IGAKI-TAMAI® (Kyoto Medical Planning, Japan).....II-8
1$100
   ReZolve® (REVA Medical Inc., US).....II-91$100
   Coronary Artery Disease-A Perspective.....II-10
Treatment Options for Coronary Artery Disease.....II-10
Percutaneous Coronary Intervention (PCI).....II-10
Coronary Stenting.....II-10
1$100
   Types of Coronary Stents.....II-11
Bare Metal Stents (BMS).....II-11
Drug Eluting Stents (DES).....II-11
1$100
   Bioabsorbable Stents.....II-12
Design and Composition of Bioabsorbable stents.....II-12
Different Types of Bioabsorbable Stents.....II-12
Metallic Bioabsorbable Stents.....II-12
1$100
   Polymer Bioabsorbable Stents.....II-13
Degradation Period of Select Bioabsorbable Materials.....II-13
Advantages of Bioabsorbable stents.....II-13
1$100
   Challenges.....II-141$100
   Other Treatment Options for Coronary Heart Disease.....II-15
Coronary Artery Bypass Grafting (CABG).....II-15
Minimally Invasive Direct Coronary Artery Bypass (MIDCAB).....II-15
TransMyocardial Laser Revascularization (TMR).....II-15
Peripheral Arterial Disease: Understanding the Stealthy Peril.....II-15
1$100
   Treatment for PAD.....II-16
Lifestyle Changes.....II-16
Medication.....II-16
1$100
   Surgery.....II-17
Stenting- A Treatment Option for PAD.....II-17
1$100
   Definition of Key Endpoints Used for Assessing Efficiency of Stents.....II-18
MACE (Major Adverse Cardiac Events).....II-18
Restenosis.....II-18
Stent Thrombosis.....II-18
1$100
   Target Lesion Revascularization (TLR).....II-191$100
   Abbott Laboratories Launches Absorb™ BVS in Europe and Other Select
  Geographies.....II-20
1$100
   Abbott Laboratories Initiates ABSORB III Clinical Trial in the US.....II-21
ART Conducts First-in-Human Implant of ART Bioabsorbable Stent.....II-21
Kyoto Medical Planning Releases Data to Demonstrate Efficacy of IGAKI-TAMAI®
  Stent.....II-21
1$100
   REVA Medical Receives Clearance to Conduct Clinical Trials for ReZolve® in Brazil and
  Germany.....II-22
Xenogenics Acquires Ideal™ BioStent Assets from Investment Funds.....II-22
1$100
   ART Discloses Data for ART Bioabsorbable Stent Platform.....II-231$100
   Abbott Laboratories (US).....II-24
Amaranth Medical, Inc. (US).....II-24
1$100
   Arterial Remodeling Technologies SA (France).....II-25
BIOTRONIK SE & Co. KG (Germany).....II-25
Elixir Medical Corporation (US).....II-25
1$100
   Kyoto Medical Planning Co., Ltd. (Japan).....II-26
REVA Medical, Inc. (US).....II-26
1$100
   Table 1: World Current and Future Analysis for Bioabsorbable Stents by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales in ‘000 Units for Years 2013 through 2018 (includes corresponding Graph/Chart).....II-271$350
   Table 2: World 6-Year Perspective for Bioabsorbable Stents by Geographic Region - Percentage Breakdown of Volume Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2013 and 2018 (includes corresponding Graph/Chart).....II-281$350
   A. Market Analysis.....III-1
Market Overview.....III-1
Growth.....III-1
Coronary Artery Disease - A US Perspective.....III-1
Baby Boomers Boost Coronary Stent Market.....III-1
1$140
   Challenges Ahead.....III-2
Current and Future Analysis.....III-2
Products in the Pipeline.....III-2
Competitive Scenario.....III-2
Strategic Corporate Developments.....III-2
1$140
   Key Players.....III-32$280
   B. Market Analytics.....III-5
Table 3: The US Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2018 (includes corresponding Graph/Chart).....III-5
1$200
   A. Market Analysis.....III-6
Overview.....III-6
Growth Drivers.....III-6
Cardiovascular Disease in Europe – A Perspective.....III-6
Highly Diverse Europe.....III-6
1$140
   Product Launch.....III-7
Strategic Corporate Developments.....III-7
2$280
   Key Players.....III-91$140
   B. Market Analytics.....III-10
Table 4: European Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2018 (includes corresponding Graph/Chart).....III-10
1$200
   A. Market Analysis.....III-11
Overview.....III-11
A Few Key Facts.....III-11
Asia-Pacific - A Price Sensitive Market.....III-11
Growth drivers.....III-11
1$140
   Current and Future Analysis.....III-12
A Regional Perspective.....III-12
Japan.....III-12
Prospects Weighed down by Regulatory Entanglements.....III-12
Japanese Coronary Stents Command Higher Prices.....III-12
Competitive Landscape.....III-12
1$140
   China.....III-13
Healthcare Reforms to Propel Stent Market.....III-13
Strategic Corporate Development.....III-13
Kyoto Medical Planning Co., Ltd. – A Key Player.....III-13
1$140
   B. Market Analytics.....III-14
Table 5: Asia-Pacific Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2018 (includes corresponding Graph/Chart).....III-14
1$200
   Market Analysis.....III-15
Table 6: Rest of World Current and Future Analysis for Bioabsorbable Stents with Annual Sales in ‘000 Units for Years 2013 through 2018 (includes corresponding Graph/Chart).....III-15
1$200
  
Total Companies Profiled: 16 (including Divisions/Subsidiaries - 17)

Region/Country Players

The United States 9 Japan 1 Europe 4 France 1 Germany 2 The United Kingdom 1 Asia-Pacific (Excluding Japan) 3
Click here to request a full table of contents and more details on this project.